桃红四物汤（THSWD）是经典的中药方剂，具有活血化瘀、回春补气的功效。已有 THSWD 治疗紫杉醇引起的化疗引起的周围神经病变（CIPN）的临床报告。我们进行了网络药理学和分子对接分析，以进一步阐明THSWD发挥对CIPN保护作用的分子机制。通过中药系统药理学数据库和分析平台（TCMSP）获得THSWD的化学成分及其相应的靶点，在在线人类孟德尔遗传 (OMIM)、治疗靶点数据库 (TTD)、GeneCards 和 DrugBank 等疾病数据库中检索 CIPN 的相关靶点。 THSWD 和 CIPN 之间的共同目标是使用维恩图确定的。使用相互作用基因/蛋白质检索搜索工具（STRING）构建蛋白质-蛋白质相互作用（PPI）网络，然后进行基因本体论（GO）和京都基因和基因组百科全书（KEGG）途径富集分析。利用AutoDock和PyMOL对THSWD的关键成分与核心靶点进行分子对接验证。共鉴定出THSWD的69个化学成分，对应856个靶点； 2,297 个目标与 CIPN 相关，其中有 105 个共同目标的交集。 PPI分析确定了8个核心靶标：MYC、TNF、MAPK14、AKT1、ESR1、RELA、TP53和HSP90AA1； KEGG富集分析涉及PI3K-Akt、NF-κB、HIF-1等信号通路。分子对接结果表明，所选活性成分与其对应的靶蛋白具有良好的结合活性。通过网络药理学，本研究发现： THSWD在治疗CIPN方面具有显着优势。通过分析潜在的核心靶点、生物学功能和涉及的信号通路，我们阐明了THSWD治疗效果的潜在分子生物学机制。本研究为THSWD治疗CIPN.2024转化癌症研究的临床应用提供理论依据。版权所有。

Taohong Siwu decoction (THSWD) is a classic traditional Chinese medicine (TCM) formula known for its effects in promoting blood circulation, removing blood stasis, and rejuvenating energy. There have been clinical reports of THSWD treating chemotherapy-induced peripheral neuropathy (CIPN) caused by paclitaxel. We conducted a network pharmacology and molecular docking analysis to further clarify the molecular mechanisms by which THSWD exerts its protective effects against CIPN.Chemical components of THSWD and their corresponding targets were obtained through the traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP), and related targets of CIPN were searched in disease databases including Online Mendelian Inheritance in Man (OMIM), Therapeutic Target Database (TTD), GeneCards, and DrugBank. Common targets between THSWD and CIPN were identified using Venn diagrams. A protein-protein interaction (PPI) network was constructed using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), which was followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. AutoDock and PyMOL were used for the molecular docking validation of the key components of THSWD with core targets.At total of 69 chemical components of THSWD were identified, corresponding to 856 targets; 2,297 targets were associated with CIPN, with an intersection of 105 common targets. PPI analysis identified eight core targets: MYC, TNF, MAPK14, AKT1, ESR1, RELA, TP53, and HSP90AA1; KEGG enrichment analysis implicated signaling pathways such as PI3K-Akt, NF-κB, and HIF-1, etc. Molecular docking results indicated that the selected active components and their corresponding target proteins have good binding activity.Through network pharmacology, this study found that THSWD has significant advantages in treating CIPN. By analyzing potential core targets, biological functions, and involved signaling pathways, we clarified the potential molecular biological mechanisms involved in THSWD's treatment effect. This study provides a theoretical basis for the clinical application of THSWD in treating CIPN.2024 Translational Cancer Research. All rights reserved.